Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of CNTO 148 in severe persistent asthma
2004-000046-21Phase 2Completed
- Sponsor
- Janssen Biotech
- Start
- Aug 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in severe asthma comparing CNTO 148 (dose-ranging) with Placebo (2 arms). Primary endpoints: Change in prebronchodilator percent predicted FEV1 at week 24 and Number of severe asthma exacerbations. Started Aug 2004; status: completed.
02
Drugs
golimumab
03
Conditions
severe asthma
Beyond the preview
Go deeper on 2004-000046-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000046-21.